Treatment with investigational oral therapy BIIB122/DNL151 safely lowered the activity of disease biomarkers that reflect LRRK2 activity, a protein whose mutations are associated with Parkinson’s disease, according to results from two Phase 1 clinical studies.
Oral BIIB122/DNL151 Safely Lowers LRRK2 A... - Cure Parkinson's
Oral BIIB122/DNL151 Safely Lowers LRRK2 Activity in Phase 1 Trials
Written by
Kia17
To view profiles and participate in discussions please or .
5 Replies
•
They are off to a good start. Look forward to a future phase 2 trial with data on disease modifying effect.
Actual press release from Denali here:
Definitely one to watch
Thanks for posting! Very encouraging!
Hopefully this is a cure, pray 🙏🙏🙏 thanks for sharing!
Not what you're looking for?
You may also like...
Phase 3, the Lighthouse study, Biogen and Denali, LRRK2 inhibitor BIIB122; New clinical trial registered
individuals with LRRK2-associated #Parkinsons
https://clinicaltrials.gov/ct2/show/NCT05418673...
Phase 4 study to evaluate efficacy of orally administrated Trehalose in individuals with idiopathic & LRRK2-associated Parkinsons
idiopathic & LRRK2-associated #Parkinsons...
Active recruitment for stem cell trial
the link to learn more about study details
https://www.hopebio.org/study?Name=HBPD04
Phase 3 trial of buntanetap for early-stage Parkinson’s nears end
visit in a Phase 3 trial testing buntanetap in people with early-stage Parkinson’s disease.
Read...
Related Posts
Parkinson's Disease Clinical trial for First in Humans use of FGF-1 to treat Parkinson's Disease started by Zhittya Genesis Medicine.
Phone call w/ Stem Cell Trial- Preclinical- 10 PWP ASAP. Participate in the preclinical to be first to have chance at phase 1 clinical. 
Blue Rock Stem Cell Phase 1 Success - Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson's Disease
Clinical trial suggests Parkinson's drug is safe in humans
